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Since its approval in 1979 cisplatin has become an important component in chemotherapy regimes for
the treatment of ovarian, testicular, lung and bladder cancers, as well as lymphomas, myelomas and
melanoma. Unfortunately its continued use is greatly limited by severe dose limiting side effects and
intrinsic or acquired drug resistance. Over the last 30 years, 23 other platinum-based drugs have entered
clinical trials with only two (carboplatin and oxaliplatin) of these gaining international marketing
approval, and another three (nedaplatin, lobaplatin and heptaplatin) gaining approval in individual
nations. During this time there have been more failures than successes with the development of 14 drugs
being halted during clinical trials. Currently there are four drugs in the various phases of clinical trial
(satraplatin, picoplatin, LipoplatinTM and ProLindacTM). No new small molecule platinum drug has
entered clinical trials since 1999 which is representative of a shift in focus away from drug design and
towards drug delivery in the last decade. In this perspective article we update the status of platinum
anticancer drugs currently approved for use, those undergoing clinical trials and those discontinued
during clinical trials, and discuss the results in the context of where we believe the ﬁeld will develop over
the next decade.
Introduction
Since the discovery of the therapeutic potential of cis-
diamminedichloridoplatinum(II), or cisplatin, by Barnett Rosen-
berg (1926–2009)1 it has become one of the major drugs in
cancer chemotherapy. Today it is used in 32 of 78 treatment
regimes listed in Martindale2 in combination with a wide range
of other drugs including: topoisomerase II inhibitors (doxoru-
bicin, etoposide, mytomycin, bleomycin and epirubicin), mustards
(cyclophosphamide, melphalan and ifosfamide), antimetabolites
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(gemcitabine, 5-ﬂuorouracil (5-FU) and methotrexate), vinca
alkaloids (vinblastine and vinorelbine) and taxols (paclitaxel).2
Cisplatin is currently used to treat testicular cancer (for which it
has a 90% cure rate), ovarian, bladder, melanoma, non-small cell
lung cancer (NSCLC), small cell lung cancer (SCLC), lymphomas
and myelomas.2,3
In the blood stream where the chloride concentration is
relatively high (100 mM) the chloride ligands stay attached to
the drug although binding to serum proteins, such as human
serum albumin, does occur (Fig. 1).4 When it reaches the tumour,
cisplatin is thought to be taken up into the cells by three possible
mechanisms: passive diffusion, copper transporter proteins (e.g.
CTR1) and/or organic cation transporters.5 Once inside the
cell, the lower chloride concentration (4–20 mM) results in drug
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Fig. 1 Simpliﬁed biological processing of cisplatin inside cells showing
(blue) drug aquation, (red) DNA binding through the N7 of guanine
and (green) deactivation and degradation by the tripeptide L-glutathione.
Charges have been omitted for charity.
aquation with the loss of one or both of the chloride ligands.4
When aquated, cisplatin can go on to bind to its target, DNA.
Cisplatin will bind at the N7 position of guanine, and to a lesser
extent adenine, through the formation of a covalent coordinate
bond with the lone pair of the nitrogen atom.4 Ring closure
through the formation of a second DNA bond forms a range
of adducts, particularly 1,2-GpG intrastrand adducts that bend
the DNA (between 30 and 60◦ towards the major groove) and
unwinds the helix (up to 23 ◦).6 This DNA distortion prevents
replication and transcription, which ultimately leads to cellular
apoptosis.4 Cisplatin is also known to bind to RNA and interfere
with cellular RNA processing, which may assist in the action of
the drug.7
Unfortunately, the use of cisplatin is restricted because of severe
dose-limiting side effects which arise from the indiscriminate
uptake of the drug into all rapidly dividing cells (tumours,
but also for example bone marrow) and the body’s attempt
to excrete the drug through the kidneys. These side effects
include: nephrotoxicity (reduced kidney function and damage),
neurotoxicity (nervous system damage), ototoxicity (hearing loss),
and myelosuppression (reduction in bone marrow activity). To
somedegree the nephrotoxicity of cisplatin can be reduced through
the use of saline hyperhydration before and after treatment.8 As a
single agent, cisplatin does not cause alopecia (hair loss).
The severe side effects of cisplatin mean that the dose delivered
to patients can be sub-lethal to tumours, particularly ovarian
cancers, which means they are then able to develop resistance
to further drug treatment. There are three main mechanisms of
drug resistance:9
∑ Reduced drug uptake and/or increased drug efﬂux.
∑ Degradation and deactivation by intracellular thiols. In
particular this may be due to raised glutathione levels which can
be as high as 10 mM inside resistant cells.
∑ Improved repair or tolerance of DNA–cisplatin adducts.
The toxicity of, and cellular resistance to, cisplatin have driven
the development of improved platinum-based anticancer drugs
that display fewer or more tolerable side effects and/or are
able to overcome one or more resistance mechanisms. In the
30 years since cisplatin’s ﬁrst approval for human use, 23 other
platinum-based drugs have entered clinical trials with only two
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Table 1 Platinum-based anticancer drugs which have achieved marketing approval for human use in at least one nation state
Drug
Other names/brand
names/formulation names CAS number
Development
company/Marketer DLT Country
Cisplatin Platinol R© Briplatin 15663-27-1 Generic Nephrotoxicity Global
Platidiam Abiplatin R©
Platinex R© Lederplatin
Platistin Neoplatin
Platosin Platibastin
Cisplatyl Peyrone’s
Platiblastin R© chloride
Carboplatin Paraplatin R© JM 8 41575-94-4 Generic Myelosuppression Global
Paraplatine Cycloplatin
Carbomedac R© CBDCA
Carbosin Ribocarbo
Oxaliplatin Eloxatin R© Dacplat R© 61825-94-3 Sanoﬁ-Aventis Neurotoxicity Global
Dacotin R© Elplat R©
Nedaplatin Aqupla R© 254-S 95734-82-0 Shionogi Pharmaceuticals Myelosupression Japan
NSC375101D
Lobaplatin — — 135558-11-1 Asta-Medica Thrombocytopenia China
Heptaplatin Sunpla SKI 2053R 146665-77-2 SK Chemicals Life Sciences Nephrotoxicity/ Korea
Eptaplatin Intra-abdominal
bleeding
NSC-644591
NSC-D-644591
gaining global approval and another three gaining marketing
approval in individual nations. In this perspective we appraise the
current status of platinum drugs in the clinic and those currently
undergoing clinical trials. We also examine those drugs whose
developmentwas halted during clinical trials anddiscuss the future
of platinum drug development.
Clinically approved drugs
A list of platinum-based anticancer drugs which have achieved
marketing approval for human use in at least one nation state is
given in Table 1.
Carboplatin (approved world-wide)
The toxicity of platinum-based drugs is directly related to
the ease with which the leaving groups are aquated. Platinum
complexes with highly labile ligands, such as water or nitrate,
are very toxic whereas ligands such as bis-carboxylates, which
aquates very slowly, are signiﬁcantly less toxic. Diammine[1,1-
cyclobutanedicarboxylato(2-)-O,O¢]platinum(II) was designed
speciﬁcally to reduce the side effects associated with cisplatin
treatment (Fig. 2). This is achieved through the replacement of
the dichloride ligands with 1,1-cyclobutanedicarboxylate, which
aquates with a rate constant of 10-8 s-1, compared with 10-5 s-1 for
cisplatin.10,11
Because of its lower reactivity, carboplatin can be administered
in much higher doses (300–450 mg m-2) than cisplatin (20–120 mg
m-2), depending on the administration schedule.2 The side effects
of carboplatin are also different with leukopenia, neutropenia and
thrombocytopenia as the dose limiting toxicities (DLTs). Once
aquated carboplatin yields the same active component as cisplatin
and forms the same DNA adducts, and is therefore only clinically
Fig. 2 Theplatinum-based anticancer drugswhich have gainedmarketing
approval for human use in at least one nation state.
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useful for treating the same cancer types. Carboplatin is now
the drug of choice for ovarian cancer, in preference to cisplatin,
and has recently undergone additional Phase II and III trials for
the treatment of salivary gland cancer12 and advanced mullerian
cancer13 to further expand its clinical application.
Oxaliplatin (approved world-wide)
[Oxalate(2-)-O,O¢][1R,2R-cyclohexanediamine-N ,N¢]platinum-
(II) was the ﬁrst drug approved that was capable of overcoming
cisplatin resistance. In oxaliplatin the two ammine ligands have
been replaced by a single bidentate ligand, (1R,2R)-cyclohexane-
1,2-diamine (R,R-dach).4 Oxaliplatin is thought to overcome
cisplatin resistance through the different adducts it forms with
DNA.14 Whilst it predominantly forms GpG intrastrand adducts,
the bulky hydrophobic dach ligand points into the DNA major
groove which prevents binding of DNA repair proteins.15 The
oxalate ligand also greatly reduces the severity of the side effects
of the drug compared with cisplatin.14
Oxaliplatin was ﬁrst approved in France in 1996, the USA in
2002 and Japan in 2005. The drug was developed and marketed
throughout the world by Sanoﬁ-Aventis and whilst the Food and
Drug Administration in the USA (the biggest pharmaceutical
market in the world) approved generic formulations of the drug
in August 2009, deals between Sanoﬁ-Aventis and six generics
manufactures means all will stop selling alternative versions of
oxaliplatin by 30 June 2010 until 09 August 2012. Until then
sales were worth more than US$1.3 billion per year. Oxaliplatin
currently has wide approval for the treatment of adjuvant and
metastatic colorectal cancers when used in combination with 5-
FU and folinic acid.2 Recent clinical trials have tried to extend
its spectrum of activity to include the treatment of metastatic
gastric and oesophagogastric adenocarcinoma,16 and improve its
effectiveness against colorectal cancers through its administra-
tion with different drugs such as irinotecan and capecitabine.17
Ongoing clinical trials as of April 2010 include examination for
efﬁcacy in gastric, fallopian tube and ovarian, breast, NSCLC,
pancreatic cancers, acute myeloid leukaemia, indolent lymphoma,
and heptoma.
Nedaplatin (approved in Japan)
Diammine[hydroxyacetato(2-)-O,O¢]platinum(II) is a second-
generation platinum analogue that is ten times more water
soluble than cisplatin, and is signiﬁcantly less nephrotoxic than
both cisplatin and carboplatin.18,19 Preclinical and clinical studies
demonstrated that nedaplatin has anticancer activity superior
to that of carboplatin and equivalent to that of cisplatin.19,20
Since its approval in 1995, it has been used in the treatment
of NSCLC, SCLC, oesophageal cancer and head and neck
cancers.19,21 The MTD of nedaplatin is 90 mg m-2 and the DLTs
are thrombocytopenia and neutropenia.22
Recently, several Phase I and Phase II studies have shown
promising results when nedaplatin is used in combination ther-
apies. For the treatment of oral squamous cell carcinoma, a
nedaplatin and docetaxel regime gave a partial response (PR) rate
of 33%.23 Nedaplatin with paclitaxel in the treatment of metastatic
oesophageal carcinoma gave a complete response (CR) rate of 3%
and a PR rate of 41%,24 and nedaplatin with irinotecan followed
by geﬁtnib in the treatment of NSCLC had an overall response
(OR) rate of 43%.25
Two further clinical trials have been conducted to investigate the
effect of replacing cisplatin with nedaplatin in patients normally
treated with a regime of cisplatin and 5-FU for oesophageal
squamous cell carcinoma,18,26 and locoregionally advanced na-
sopharyngeal carcinoma.27 Both studies found no difference in
the overall survival rates. It was concluded, however, that replacing
cisplatin with nedaplatin may prove useful when treating cancer
patients that also present with renal impairment.18,26
Lobaplatin (approved in China)
[2-Hydroxypropanoato(2-)-O1,O2][1,2-cyclobutanedimethan-
amine-N,N¢]platinum(II) is a third-generation platinumanticancer
drug delivered as a diastereomeric mixture of S,S and R,R
conﬁgurations of the carrier ligand. The drug does not induce
alopecia,28 renal, neuro- or ototoxic side effects after either IV
bolus injection or infusion.29-33 Anaemia and leukopenia are
common,28,29,34 as are nausea and vomiting, although the latter two
can be well-controlled with antiemetics.28,29,34 The common DLT
is thrombocytopenia.28,30,32–37 Lobaplatin is currently approved
for the treatment of chronic myelogenous leukaemia (CML),
inoperable metastatic breast cancer and SCLC.38 In 2003 Ainan
Tianwang International Pharmaceutical signed a US$4.3 million
deal for manufacturing and marketing rights in China.39
Recently, lobaplatin has been trialled in combination with
vinorelbine in the treatment of late-stage NSCLC but it demon-
strated no signiﬁcant improvement in efﬁcacy compared with a
vinorelbine/cisplatin regime.40 A similar lobaplatin/vinorelbine
regime did however produce a 37% PR rate in patients treated
for advanced breast cancer with modest and recoverable non-
haematological toxicities.36 Lobaplatin with 5-FU and leucovorin
is currently undergoing Phase III trials for the treatment of
recurrent or metastatic oesophageal carcinoma.41
Heptaplatin (approved in the Republic of Korea)
[Propanedioato(2-)-O,O¢][2-(1-methylethyl)-1,3-dioxolane-4,5-
dimethanamine-N,N¢]platinum(II) was selected for clinical trials
because its in vitro and in vivo cytotoxicity was equal, or superior,
to cisplatin in various cell lines.42,43,44 It also displayed high
stability in solution,42 no remarkable toxicity42,43,44 and potent
anticancer activity towards cisplatin-resistant cells.42,44 The MTD
of heptaplatin is 480 mg m-2 with DLTs of hepatotoxicity,
nephrotoxicity and myelosuppression. It is currently used in the
treatment of gastric cancer.45,46
Since obtaining marketing approval the drug has been further
evaluated in a Phase II trial where it demonstrated an increased
response rate in combination with 5-FU and leucovorin of
38%,47 compared with 17% as a single agent.48 Previous studies
have shown that patients experience lower nephrotoxicity with
heptaplatin (360 or 400mgm-2) when compared to cisplatin (60mg
m-2),47–50 however, one randomisedPhase III study highlighted that
nephrotoxicity was more severe with heptaplatin.51
Themost recent Phase III trial comparing a heptaplatin (400mg
m-2)/5-FU regime with a cisplatin (60 mg m-2)/5-FU regime
demonstrates the survival and response rates to be comparable,
7.3 months vs. 7.9 months and 34% vs. 36%, respectively.52 The
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Table 2 Platinum(II)-based drugs which entered human clinical trials but which have not been given marketing approval
Drug Other names CAS Number Development companies Reason
JM-11 — 38780-38-0 Johnson Matthey Blood/urine clearance not better than
cisplatin
NSC 170898 PAD 38780-36-8 Wadley Institute Poor water solubility
Ormaplatin Tetraplatin NSC
363812
62816-98-2 NCI (USA)/UpJohn Severe and unpredictable cumulative
neurotoxicity
Sebriplatin CI-973, NK121 110172-45-7 Parke-Davis, Nihon Kayaku No activity in Phase II
Enloplatin CL 287,110 111523-41-2 American Cyanamid No activity in Phase II
Zeniplatin CL 286,558 111490-36-9 American Cyanamid Serious nephrotoxicity
Spiroplatin TNO-6 74790-08-2 Bristol Myers Unpredictable renal failure
Cycloplatam — 109837-67-4 N.S. Kurnakov Institute of
General and Inorganic Chemistry
Unknown
Miboplatin DWA2114R 103775-75-3 Chugai Pharmaceuticals Activity not better than cisplatin
Iproplatin JM-9 CHIP 62928-11-4 Johnson Matthey/Bristol Myers Activity not better than cisplatin or
carboplatin
TRK-710 — 173903-27-0 Unknown
SPI-77 STEALTH R©
liposomal
cisplatin, SPI-077
SPI-077 Alza Pharmaceuticals/Johnson &
Johnson
No activity in Phase II
Aroplatin L-NDDP 114488-24-3 Antigenics/Aronex
Pharmaceuticals
Economic
NDDP
BBR3464 Triplatin 172903-00-3 Novuspharma/Boehringer
Mannheim Italia/Roche
No activity in Phase II
advantage of the heptaplatin treatment was that the toxic side
effects of neutropenia and emesis were less severe and proteinuria
levels were lower.52 A supporting Phase III trial demonstrated that
the twoheptaplatin/5-FUregimes (34 and36%response rate)were
comparable with a cisplatin/5-FU regime (response rate 34%).53
Discontinued drugs
In order to develop drugs that are more cytotoxic to cancers
and have fewer and/or less severe side effects, it is important to
know what drugs have previously undergone clinical trials but
subsequently failed either due to a lack of activity or because
of their toxicity (Table 2). In some instances drugs may also be
discontinued in clinical trials simply for economic reasons. To
date, 14 platinum-based drugs (Fig. 3) have completed at least one
Phase I trial with only a few reaching Phase III.
JM 11
Dichloridobis(isopropylamine)platinum(II) was one of the ﬁrst
cisplatin-derivatives tested as a potential drug candidate. In vivo
trials demonstrated a therapeutic index superior to cisplatin in
ADJ/PC6 tumour xenografts (JM 11: 25, cisplatin: 8.1) and a
similar increase in life span for mice with L1210 leukaemia (70 and
95%, respectively).54–56 JM 11 underwent a single Phase I trial, not
to evaluate drug DLT or MTD but to examine pharmacokinetics
in comparison to cisplatin. At a single dose of 27 mg, it was found
that the blood and renal clearances were not signiﬁcantly different
from cisplatin with no evidence of tumour uptake. As such, drug
development was abandoned.57,58
NSC 170898
Dichloridobis(cyclopentylamine)platinum(II) is a simple deriva-
tive of cisplatin where the ammines of cisplatin have been
functionalised with cyclopentylamine ligands.56 Despite its very
poor water solubility, in vivo testing showed that the drug was
less toxic than cisplatin and had a much better therapeutic index
(200–235) compared with cisplatin (8.1) in PC6 tumour bearing
mice.54,56 NSC170898, however, was less effective than cisplatin in
treating L1210 with an increase in life span of only 41% compared
with 95% for cisplatin.56 This drug underwent a single Phase I trial
but was not further developed because of its poor solubility.59,60
Ormaplatin
Tetrachlorido(1,2-cyclohexanediamine-N,N¢)platinum(IV) is a
prodrug that undergoes reduction by proteins with sulfhydryls
groups (t1/2: 5–15 min) in tissue and blood plasma to dichlorido-
(D,L-trans-1,2-diaminocyclohexane)platinum(II).61 Upon aqua-
tion inside the cell, it yields a similar active component to
oxaliplatin, although in ormaplatin the carrier ligand is a mix
of the D- and l-isomers of the diaminocyclohexane ligand.
Ormaplatin was chosen from a family of 28 similar complexes62,63
because of its in vitro and in vivo activity in L1210 leukaemia,64
A2780/CP70 ovarian,65 B16 melanoma, myeloma and mammary
cancers.64,66
Six Phase I clinical trials were conducted under the sponsorship
of the National Cancer Institute (USA) examining single monthly,
weekly ¥ 2 (a single weekly dose given for two consecutive weeks),
daily ¥ 5 (a single daily dose given for ﬁve consecutive days) and
intraperitoneal administration regimes of ormaplatin.66–68 In the
regular multiple dosing trials cumulative severe neurotoxicity (at
total doses greater than 200 mg m-2) was the DLT and in two trials
a safe MTD could not be determined.66,68 As a single monthly
IV infusion, a safe dose of 98 mg m-2 was recommended for
Phase II trials, with myelosuppression (thrombocytopenia and
granulocytopenia) the DLT.67 As with the multiple dosing trials,
cumulative neurotoxicity was also observed. In total more than
118 patients have been treated with ormaplatin. No Phase II trials
of ormaplatin have been reported in the literature.
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Fig. 3 The platinum-based anticancer drugs which entered human
clinical trials, but their development was not continued because of
severe/unpredictable side effects from Phase I, because of a lack of activity
in Phase II/III trials, or for economic reasons. Cycloplatam: where R =
OH, R¢ = H and where R = H, R¢ = OH.
Sebriplatin
[1,1-Cyclobutanedicarboxylato(2-)-O,O¢](2-methyl-1,4-butane-
diamine-N,N¢)platinum(II) which contains the same leaving group
as carboplatin, displayed better cytotoxicity than cisplatin in 24
of 37 cisplatin sensitive and resistant cancer cell lines tested.69 In
particular the drug demonstrated some potential in overcoming
cisplatin resistance in ovarian cancer and considerable potential as
a treatment for leukaemia;69–72 a cancer in which platinum drugs
have never showed efﬁcacy in humans. Sebriplatin also demon-
strated synergies when co-administered with hyperthermia.73,74
Two Phase I trials were completed with sebriplatin as a daily ¥
5 and a once monthly IV infusion.75,76 In the multiple dosing
trial neutropenia was the DLT, but was rapidly recoverable,
with mild/infrequent vomiting and nausea.75 The MTD was
determined to be 40–50 mg m-2 from which a Phase II dose of
30 mg m-2 day-1 for 5 days was recommended.75 In the once
monthly trial a MTD of 290 mg m-2 was determined with
granulocytopenia as the DLT for patients previously untreated
with platinum, radiation or stem cell toxin therapy, and a MTD
of 230 mg m-2 for those who had previously been treated with at
least one of these regimes.76 Doses of 230 and 190 mg m-2 were
recommended for Phase II trials in these groups of patients.
A single Phase II study has been reported for metastatic breast
cancer, treated with 230 mg m-2 of sebriplatin once every 21 days.77
Two partial responses were observed and several minor responses.
Whilst the results indicated that further examination of that dose
and schedule were not warranted, the authors hypothesised that
the drug may be more efﬁcacious at higher doses if colony-
stimulating factors were also used.77 No other Phase II trial results
have been reported in the literature.
Enloplatin
[1,1-Cyclobutanedicarboxylato(2-)-O,O¢][tetrahydro-4H-pyran-
4,4-dimethylamine-N,N¢]platinum(II) is a water-soluble drug
(450 mg mL-1)78 with the same leaving group as carboplatin and
a carrier ligand similar to zeniplatin (see below). Preclinical trials
indicated cytotoxicity in breast,78 ovarian, cisplatin resistant SCLC
and embryonal carcinoma cancers.78,79 In vivo trials of enloplatin
also displayed low renal toxicity, good physical stability and a lack
of cross-resistance with cisplatin.78,79
Initial Phase I studies indicated that nephrotoxicity was the
DLT,80 although in a later Phase II trial it was found that
the nephrotoxicity was manageable and neutropenia was dose
limiting.81 In the only reported Phase II trial in the literature, 18
patients with platinum resistant ovarian cancer were treated with
single IV dose every 21 days, without prehydration, from which
only one PR was observed.81
Zeniplatin
[1,1-Cyclobutanedicarboxylato(2-)-O,O¢][2,2-bis(aminomethyl)-
1,3-propanediol-N,N¢]platinum(II) was selected for development
from a family of 20 structurally related complexes.78 Whilst the
drug was less active than cisplatin and carboplatin in P388, L1210
andL1210CPR cells in vivo, it showed comparable activity inMX-
1 breast and H207 tumour xenografts and higher cytotoxicity in
B-16melanoma andM5076 reticulum sarcoma cells.78 In addition,
it is signiﬁcantly more water soluble (7 mg mL-1) than cisplatin
(2 mg mL-1) and has less severe side effects.78
Phase I results showed that zeniplatin had aMTDof 145mgm-2,
with leukopenia and neutropenia the DLTs.82 In total, zeniplatin
was tested in 308 Phase II patients with advanced ovarian,83,84
breast,85 advanced malignant and metastatic melanomas,86,87 ad-
vanced renal,86 and advanced NSCLC.88 The response rates were
generally poor with a PR rate of 10–14%. Only two patients were
reported to have achieved a CR (with lymph-node metastasised
melanoma).86 Clinical development of the drug was halted due
to serious nephrotoxicity, even with prehydration, which was not
seen previously in clinical trials or in animals.86 In another study,
16% of patients also experienced a fever of unknown origin.84
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Spiroplatin
[Sulfato(2-)-O,O¢][1,1-cyclohexanedimethylamine-N ,N¢]plati-
num(II) was discovered and developed in the Netherlands. This
drug is unique in that it is the only one to have reached clinical
trials with a sulfato ligand as the leaving group which binds to the
platinum through the oxygen atoms.
Phase I trial results gave aMTD from a single IV infusion of 35–
40mgm-2 or from a daily ¥ 5 infusion of 8–9mgm-2.89,90 TheDLTs
were myelosuppression (leukopenia and thrombocytopenia) in
both trials.89,90 A CR was seen in one patient with lung metastased
breast cancer and one PR for a patient with adenocarcinoma of
the lung.89
Phase II trials evaluated spiroplatin in a range of cancer
types including renal cell carcinoma, ovarian and malignant
melanoma.91,90 In the ﬁrst trial patients with advanced ovarian
carcinoma were given a once monthly IV infusion of 30 mg m-2
but none of the patients displayed cancer remission.91 In the second
trial patients were given a 30 mg m-2 infusion every three weeks. Of
the 64 people treated only three patients showed a response.92 The
lack of drug activity and subsequent unpredictable severe renal
toxicity (renal toxicity was observed in Phase I trials but it was not
severe) meant the drug did not move into Phase III trials.91,92
Cycloplatam
[Hydroxybutanedioato(2-)-O1,O4][ammine(cyclopentanamine)]-
platinum(II) was discovered and developed in Russia by the
N.S. Kurnakov Institute of General and Inorganic Chemistry.
Cycloplatam was used in two different chiral forms, with the
hydroxyl on the leaving group in either the cis or trans position in
relation to the cyclopentane ring of the carrier ligand.93 Preclinical
trials indicated drug activity in vitro in a range of cancer cell
lines (mainly ovarian cancer cell lines), with some ability to
overcome cisplatin-resistance, and in vivo activity in human
tumour xenografts (particularly lung cancer).93 All publications
dealing with the clinical trials of cycloplatam have been published
only in Russian, but it is known that cycloplatam was examined
in Phase II trials as a treatment for urinary bladder, cervical
carcinoma, prostate and pleural mesothelioma.94
Miboplatin
[1,1-Cyclobutanedicarboxylato(2-)-O,O¢][(R)-2-aminomethyl-
pyrrolidine-N,N¢]platinum(II) contains an unsymmetric alicyclic
diamine as the carrier ligand and was selected for further clinical
studies due to its good water solubility,95,96 lower nephrotoxicity
and potent anticancer activity in prostate, breast, colon, ovarian,
oesophageal and pancreatic cancer. In contrast to cisplatin, in vitro
studies have shown that the anticancer effect of miboplatin is time
dependent.97 It is more potent when administered at multiple low
doses compared with a high single bolus injection.97,98An in vivo
study investigating the increase in survival time of leukaemia
bearing mice demonstrated synergism when miboplatin was ad-
ministeredwith adriamycin or vindesine, whereas cisplatin showed
sub-additive cytotoxicity with the same drugs.95
In Phase I clinical trials the DLTs of miboplatin were gastro-
intestinal toxicity and neutrocytopenia at a MTD of 1200 mg
m-2 day-1.98 The recommended dose for Phase II trials was 800 mg
m-2 as a 1 h IV infusion repeated every three to four weeks.98 In
Phase II clinical trials, miboplatin achieved an OR rate of 44%
in the treatment of ovarian cancer and 21%, with one CR, in the
treatment of breast cancer.99
In Phase III trials the effectiveness of miboplatin was compared
with cisplatin against ovarian cancer. A response rate of 39%
was achieved with miboplatin and 47% with cisplatin.100 In
a separate Phase III clinical trial miboplatin at 800 mg m-2
was compared to cisplatin at 50 mg m-2 (both in combination
with cyclophosphamide and doxorubicin), where the cisplatin
regime displayed superior cytotoxicity.95 The lower effectiveness
of miboplatin compared with cisplatin in both trials meant drug
development was abandoned.96
Iproplatin
cis,trans,cis-Dichloridodihydroxidobis(isopropylamine)platinum-
(IV) is an octahedral-based drug similar to ormaplatin, in that it
is reduced in vivo to a platinum(II) species that then undergoes
aquation and DNA binding.101 Of all the platinum-based drugs to
enter human clinical trials but which failed to achieve marketing
approval, iproplatin is by far the most studied, with ﬁve Phase I,
22 Phase II and a single Phase III trial, involving more than 1000
individual patients, reported in the literature.
Phase I trials demonstrated that myelosuppression, particularly
cumulative thrombocytopenia,102 was the DLT at a MTD of
350 mg m-2 as a single IV infusion every three weeks, but
with a recommended dose of 300 mg m-2 for Phase II trials.
Patients treated on a daily ¥ 5 schedule every three weeks had
a recommended Phase II dose of 45–65 mg m-2;103 or 95 mg m-2
when administered weekly ¥ 4 with a two week break before the
next course.104
Drug activity was examined in a variety of cancer types in
Phase II, including: ovarian,105 urothelial,106 malignant pleural
mesothelioma,107 breast,108–111 squamous cell carcinoma, paediatric
disseminated neuroblastoma and other pediatric malignant solid
tumours,112–114 germ cell carcinomas,115,116 adenocarcinoma of
the upper gastro-intestinal tract,117 colorectal,118–120 cervical,121,122
SCLC and NSCLC,123,124 squamous cell carcinoma of the head
and neck,125 and testicular cancers.126 Patients included those
previously untreated and treated with other chemotherapeutics,
including platinums. Iproplatin was largely inactive in themajority
of these tumour types and in many cases where it was active,121 it
was found to be less effective than either cisplatin or carboplatin
(the latter of which was undergoing Phase II trials at the same
time).114,117,122 Advancement of the drug was also hindered by
occasional toxic deaths and dose reductions due to cumulative
thrombocytopenia.108,119,126 Only one Phase III trial of iproplatin
has been reported, for ovarian cancer, where it was administered
in combination with cyclophosphamide and compared to similar
regimes using cisplatin or carboplatin from this trial.127 It was
concluded that the iproplatin response rate was not different from
cisplatin.127
TRK-710
[3-Acetyl-5-methyl-2,4(3H ,5H)-furandionato-O3,O4][1,2-cyclo-
hexanediamine-N,N¢]platinum(II) demonstrated activity in en-
dometrial and NSCLC with similar efﬁcacy to cisplatin at
equimolar concentrations.16,128 Furthermore, it displayed activity
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in cisplatin resistant cell lines associated with a higher uptake rate
compared to cisplatin.16,128 A Phase I trial showed that TRK-710
displayed lower nephrotoxicity and myelosuppression compared
with cisplatin.129 No other Phase I or II results have been reported.
SPI-077
This drug is a liposomal formulation of cisplatin which utilises
steric stabilisation to avoid rapid clearance by macrophages.130
Encouraging preclinical activity was accredited to prolonged
circulation time and enhanced tumour uptake in a variety of
tumour models with minimal and reversible toxicities.131–134
Treatment in Phase I and II clinical trials was generally well
tolerated with little or no haematological, renal, hepatic, gastro-
intestinal or neurological toxicities and no requirement for routine
hydration.130,135–139 Dose escalation studies with single agent SPI-
077 up to 420 mg m-2 did not reach a MTD but were instead
limited by infusion volume, which was increased to control
infusion reactions.139–141 A lack of clinical activity despite the
administration of large doses, coupledwith an apparent absence of
cisplatin related toxicities raised concerns over the bioavailability
of cisplatin from the liposomes.130,138,142–144 A pharmacokinetic
study revealed platinum–DNA adduct levels in white blood cells
were more than ten-fold lower than after comparable doses of
non-liposomal cisplatin.139 In vitro studies conﬁrmed negligible
(< 10%) release from the liposomes, with extremely slow release
kinetics.131,135 Reformulationwas recommended in order to achieve
liposomes which were more permeable to cisplatin once exposed
to the hypoxic and acidic tumour environment.130,135,138,139,144
More recently, low frequency ultrasound (LFUS) has been
shown to facilitate the release of cisplatin from the liposomes.145
Such use of LFUS may improve therapeutic efﬁcacy of liposomal
formulations but is likely to be practicable only for superﬁcial
tumours.146
AroplatinTM
Also known as L-NDDP consists of a lipophilic cisplatin
analogue, cis-bis-neodecanaota-trans-(1R,2R-diaminocyclo-
hexane)platinum(II), liposomally encapsulated in a 7:3 ratio
of dimyristoyl phosphatidylcholine (DMPC) and dimyristol
phosphatidylglycerol (DMPG)with a drug to lipid ratio of 1 : 15.147
Preclinical studies have demonstrated that the bioavailability
of NDDP is dependent on liposomal encapsulation.147,148 The
DMPG component is important for moderating stability and
anticancer activity148–151 as it enhances the acidic environment of
the liposomal suspension and hence increases the conversion of
the NDDP prodrug to the active moiety.152
L-NDDP exerted equal cytotoxicity in cells lines both sen-
sitive and resistant to cisplatin (human ovarian151 and colon
carcinoma153) and displayed increased activity compared to cis-
platin in liver metastases,148 no nephrotoxicity in dogs154 and no
cross resistance with cisplatin both in vitro and in vivo.150,151,153
It has been proposed that the most likely mechanism for cellular
uptake is a direct cellmembrane to liposome interactionwith rapid
exchange of NDDP.148 Anticancer activity is exerted via chemical
activation by forming one or more active intermediates in situ by
intercalating between phospholipid molecules of the bilayer.150,152
A Phase I trial on patients with metastatic tumours examining
delivery by single IV injection every four weeks determined the
MTD to be 312 mg m-2 and the DLT as myelosuppression.155
A Phase II trial of this regime was undertaken in patients with
therapy-refractory advanced colorectal cancer.156 Treatment was
generally well tolerated with 45% of patients receiving a dose
escalation and the response rate was comparable to single agent
oxaliplatin.156,157
A second Phase I trial looking at intrapleural administration of
Aroplatin for 30 minutes every 21 days in patients with malignant
pleural effusions determined a MTD of 450 mg m-2 (50% higher
than IV administration) with chemical pleuritis as the DLT.158
Again no nephrotoxicity was observed and, in contrast to IV
administration, there was an absence of myelosuppression.158
A subsequent Phase II trial using intrapleural administration
achieved a 42% response rate with signiﬁcant but manageable
toxicity, however, efﬁcacy was limited to areas in direct contact
with the pleural space.159
Intraperitoneal administration was also investigated in patients
with peritoneal carcinomatosis or sarcomatosis.160 This delivery
method allows for prolonged drug exposure to the abdominal
cavity and low systemic absorption thus allowing increased drug
doses and reduced systemic toxicity.160 The MTD was 400 mg m-2
every 28 days and the DLTs were fatigue and abdominal pain.160
Until recently Aroplatin had been undergoing various Phase I
andPhase I/II trials as a single agent and in combination therapies
treating resistant pancreatic and advanced colorectal cancers,
advanced solidmalignancies andmalignant pleuralmesothelioma.
For economic reasons, however, development of Aroplatin has
now been halted.
BBR3464
[trans-Diamminechloridoplatinum(II)][(m-trans-diamminedihexa-
nediamine-N,N¢)platinum(II)] nitrate is a multinuclear plat-
inum(II) drug chosen as the lead agent from a family of di-
and trinuclear complexes.161 Whilst BBR3464 displays higher and
faster uptake into cisplatin sensitive and resistant cells,162,163 and
faster DNA binding with more DNA adducts formed compared
with cisplatin,164–166 it is the formation of a range of unique
DNA adducts that are thought to be the mechanism by which
it derives its potent cytotoxicity. Whereas cisplatin forms rigid,
short-range intrastrand adducts, the adducts ofBBR3464 aremore
commonly deﬁned as ﬂexible and long range, with a high degree of
interstrand cross-links.167–174 It is also able to induce B to Z and B
to A transitions in DNA conformation upon binding.175,176 More
recently it has been shown to be able to form phosphate clamps
with the backbone of DNA177 and have possible interactions with
membrane phospholipids.178
In preclinical in vitro and in vivo trials, BBR3464 displayed
cytotoxicity at concentrations up to 1000-fold lower than cisplatin
in sensitive cell lines and a signiﬁcant ability to overcome cis-
platin resistance in glioma, ovarian, neuroblastoma, astrocytoma,
osteosarcoma, melanoma, cervical, SCLC, NSCLC and prostatic
cells.179–186 Preclinical trials also indicated that it displayed severe
systemic toxicity, whichwas conﬁrmed in Phase I.186 TheBBR3464
MTD of 0.17 mg m-2 day-1 on a daily ¥ 5 administration produced
DLTs of neutropenia and gastro-intestinal toxicity.187 Delivery of
BBR3464 in a separate Phase I trial as a single dose every 28 days
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Table 3 Platinum-based anticancer drugs which are currently undergoing clinical trials in humans
Drug Other names CAS number Development companies
Satraplatin JM216 129580-63-8 Spectrum Pharmaceuticals and
Agennix AG (previously known
as GPC Biotech AG)
BMS 182751
BMY 45594
POplat Johnson Matthey (previous)
Orplatna R© Bristol-Myers Squibb (previous)
Picoplatin JM473 181630-15-9 Pionard (current)
NX473 NeoRex (previous)
ZD0473 Anormed (previous)
AMD0473 Johnson Matthey (previous)
ProLindacTM AP 5346 674289-90-8 Access Pharmaceuticals
LipoplatinTM NanoplatinTM Listed under the same
number as cisplatin
Regulon
Oncoplatin Nanocarrier (licensee)
gave an alternative MTD of 0.9 mg m-2.188 Subsequent Phase II
trials found the MTD was increased to as high as 1.1 mg m-2 but
in several studies the side effects experienced by some patients
resulted in a dose reduction back to 0.9 mg m-2.189
Four Phase II trials have been reported in the literature for
ovarian, SCLC, NSCLC and gastric and gastro-oesophageal
adenocarcinoma.189–192 The lack of activity observed in the gastric
and SCLC did not warrant further evaluation for these cancer
types,189,190 and although positive results were observed for some
patients in the NSCLC (two objective responses and 11 PR from
33 patients) and ovarian (ﬁve PR from 46 patients) the drug has
not moved into Phase III trials. The results of another Phase II
study of BBR3464 in locally advanced or metastatic pancreatic
cancer which started in 2001 under contract to Theradex R© and
the National Cancer Institute (USA) has yet to be reported.
Drugs currently in clinical trials
There are currently four drugs (Table 3) in various stages of
clinical trials, with two of these being close to gaining marketing
approval (satraplatin and picoplatin). Both of these drugs have
demonstrated efﬁcacy in Phase III trials and both are active
when administered orally. Two other drugs (ProLindacTM and
LipoplatinTM) will become the ﬁrst polymer/liposomal-based
platinum drugs if approved.
Satraplatin
Bis(acetato-O)amminedichlorido(cyclohexylamine)platinum(IV)
is an orally active platinum drug that has shown anti-
cancer activity against several platinum sensitive and resistant
cell lines including human lung, ovary, cervix and prostate
(Fig. 4).193–195 Satraplatin is readily absorbed by the gastro-
intestinal mucosa and once in the blood stream is reduced
to yield at least six different platinum(II) complexes with cis-
amminedichlorido(cyclohexylamine)platinum(II) being the most
active and abundant.194–197
Satraplatin was ﬁrst studied in humans on a single inter-
mittent schedule which was abandoned because of non-linear
pharmacokinetics with saturable absorption and dose limiting
vomiting and nausea.195 To improve absorption and tolerability,
satraplatin was administered on a daily ¥ 5 schedule. The MTD
Fig. 4 The platinum-based anticancer drugs which are currently under-
going clinical trials for human use. Not shown: Lipoplatin.
was determined to be 45–50 mg m-2 day-1 with DLTs of myelo-
suppression and nausea.195 Daily doses of 40–45 and 120 mg m-2
were recommended for Phase II studies for previously treated and
untreated patients, respectively.195 In another Phase I trial, seven
of eight patients with squamous cell carcinoma of the head and
neck achieved aCRwhen given 20–30mgof satraplatin three times
a week concurrently with radiotherapy.195,197 Satraplatin as a single
agent in a Phase II trial achieved a PR rate of 38% when given
120–140 mg m-2 day-1 for ﬁve days (repeated every three weeks) for
the treatment of SCLC.195 In a separate Phase II trial satraplatin at
120 mg m-2 day-1 for ﬁve days every four weeks for the treatment
of hormone refractory prostate cancer achieved a 31% PR rate.195
A Phase III trial evaluated satraplatin and prednisone against
refractory cancer (SPARC) versus placebo plus prednisone in 950
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patients with hormone refractory prostate cancer who had pro-
gressed after initial chemotherapy. It was reported that satraplatin
reduced the risk of prostate cancer progression by 40% and had
achieved a progression free survival rate of 11.1 weeks compared
to 9.7 weeks in the placebo group. As a result of these positive
results GPCbiotech ﬁled for accelerated approval of satraplatin.198
This was rejected by the FDA on the basis that satraplatin failed to
show a convincing beneﬁt in terms of overall survival and concerns
were raised that only 51% of patients in the trial had received prior
docetaxel.198,199
Currently satraplatin is undergoing a variety of Phase I, II
and III clinical trials in conjunction with various drugs such as
docetaxel in the treatment of prostate cancer, paclitaxel in the
treatment of NSCLC and capecitabine to treat advanced solid
tumours.200
Picoplatin
cis-Amminedichlorido(2-methylpyridine)platinum(II) was de-
signed primarily to circumvent glutathione-mediated drug
resistance.201–203 The pyridine ring sits nearly perpendicular to the
plane of the platinum atom, thus positioning the ligand’s methyl
group directly over the metal centre.204 This provides steric hin-
drance to the attack of the drug by nucleophiles, particularly thiols.
In vitro studies demonstrated picoplatin’s ability to overcome
platinum drug resistance, showing anticancer activity in cisplatin,
carboplatin and oxaliplatin resistant cell lines.205,206 Furthermore,
an in vivo study found the use of picoplatin resulted in greater
growth delays of human ovarian tumour xenografts in mice by
34 days compared with cisplatin (10.4 days) and carboplatin
(6.4 days).205,207
Picoplatin entered clinical trials in November 1997 and from
Phase I trials determined a MTD of 150 mg m-2 with the DLTs
being neutropenia, thrombocytopenia, nausea and vomiting.202,208
A single dose of 120 mg m-2 every 21 days was recommended
for Phase II trials.202,209 Picoplatin side-effects have also been
examined in combination with the taxanes: docetaxel and pa-
clitaxel, with docetaxel and prednisone, and with 5-FU and
leuvorin. When administered with 5-FU and leucovorin (FOLPI
regime) every four weeks the MTD remains 150 mg m-2, but
when administered once every two weeks the MTD drops to
85 mg m-2. Intravenous picoplatin administered once every
three weeks with docetaxel (75 mg m-2) and prednisone (5 mg)
as ﬁrst line treatment for patients with metastatic refractory
prostate cancer found that picoplatin increased the overall median
survival rate from 18.9 months in patients that did not receive
picoplatin to 21.4 months, with the most common side effect being
neutropenia.
Although picoplatin is well tolerated with no neuro- or nephro-
toxicity, it was withdrawn from three different clinical Phase II
trials inwhich its efﬁcacywas tested as ﬁrst and second line therapy
in advanced NSCLC and as second line in SCLC. This was due
to continued disease progression which occurred in 82% of ﬁrst-
line NSCLC patients and 82 and 77% of second-line NSCLC and
SCLC patients, respectively.209 Picoplatin is currently undergoing
various Phase I and Phase II studies as a treatment for colorectal
cancer in combination with 5-FU and leucovorin, in combination
with docetaxel for prostate cancer and as a treatment for patients
with progressive or relapsed NSCLC.200
ProLindacTM
This drug is a nanopolymer consisting of [Pt(R,R-dach)], the
activemoiety of oxaliplatin, bound to a hydrophilic biocompatible
polymer (hydroxypropylmethacrylamide, HPMA) so as to better
target solid cancers through the enhanced permeability and
retention effect.210–213 The two polymer segments are connected via
an amidomalonato chelating group and a triglycine spacer.214 The
amidomalonate–platinum chelate, attached to the platinum centre
through the nitrogen and oxygen atoms, is stable at physiological
pH210 but the low pH found in the extracellular space of hypoxic
tumours enables the sustained release of the active platinum
complex215 via breakage of these bonds.206 Investigation into the
in vitro effects of ProLindac showed that there were 20 times more
platinum–DNA adducts at pH 3 than pH 7.4, presumably due to
better drug release from the polymer at the lower pH.214
The anticancer activity of ProLindac has been assessed in mice
with B16 melanomas and ovarian carcinomas. It demonstrated
superior growth inhibition, reduced toxicity towards normal cells,
increased and more sustained plasma platinum levels, increased
delivery of [Pt(R,R-dach)] to the tumour and prolonged elevation
of platinum levels, compared with oxaliplatin.215 In a study
comparing cytotoxicity in a panel of cancer lines (including:
breast, ovarian, lung and prostate) ProLindac displayed time-
and concentration-dependent cytotoxicity of similar efﬁcacy to
oxaliplatin and was active against several cisplatin resistant cell
lines.214
In a Phase I trial, patients with advanced solid tumours were
treated with a one hour IV infusion administered on days 1, 8
and 15 of a 28-day cycle.216 The treatment was well tolerated
with no neutropenia or signiﬁcant hematologic toxicity and a
MTD of 640 mg m-2. Vomiting and nausea were controllable with
antiemetics.216 The DLT of this regime was renal insufﬁciency.216
ProLindac also showed anticancer activity in some metastatic
melanoma and advanced ovarian cancer patients.216
APhase I/II trial evaluated the anticancer activity of ProLindac
as a single agent in the treatment of advanced ovarian cancer,
where patients had previously been treated with platinums (except
oxaliplatin) at least twice.217 In this trial, weekly doses were
considered unsuitable due to the prolonged half life of ProLindac,
so patients were administered with a two hour IV infusion every
two or three weeks.217,218 Treatment was again well tolerated and
clinically-meaningful disease stabilisation was achieved in 42% of
all patients and 66% of patients who received the highest dose
(560 mg m-2 week-1 over three weeks or 1100 mg m-2 week-1
over two weeks).218 This result was comparable to single agent
oxaliplatin trialled in a less heavily pre-treated population.217 All
patients experienced at least one side effect although most were
mild at grade 1–2, and therewere no signs of acute neurotoxicity.217
Also trialled was a new ProLindac formulation made by an
improved scalable process, which the company intends to use for
future clinical trials. Access Pharmaceuticals claim that no patient
experienced any acute signiﬁcant adverse events from the new
formulation, while treatment had the same beneﬁcial sustained
biomarker decrease and disease stabilisation as seen previously.
ProLindac is currently in Phase II,217 and in early 2010 the
initiation of a combination studywas announcedwith paclitaxel in
the second-line treatment of pre-treated advanced ovarian cancer
based upon good results of the oxaliplatin/paclitaxel regime.219
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Synergistic effects have been observed previously with 5-FU,
gemcitabine, docetaxel and SN-38.214
LipoplatinTM
Lipoplatin is a liposomally encapsulated form of cisplatin devel-
oped in an effort to reduce cisplatin’s systemic toxicity proﬁle and
allow administration of greater doses whilst improving targeting
to primary tumours and metastases.220–222
The nanoparticulate liposomes are reverse-miscelles,222
composed of dipalmitoyl phosphatidyl glycerol (DPPG),
soy phosphatidyl choline (SPC-3), cholesterol and methoxy-
polyethylene glycol-distearoyl phosphatidylethanolamine
(mPEG2000-DSPE).222,223 Lipoplatin crosses cell membranes
more easily than native cisplatin due to the fusogenic nature
of the DPPG lipids.222 In addition, the presence of a PEG
coating prevents detection by immunogenic entities.222 Enhanced
circulation time in body ﬂuid and small particle size (90–130 nm)
mean the liposomes preferentially extravasate to tumours through
their leaky and/or compromised vasculature.222–224
Phase I trials in pancreatic cancer225 and NSCLC226 patients in
combination with 1000 mg m-2 gemcitabine found MTDs of 100
and 120 mg m-2, respectively.215,216 These regimes produced almost
negligible nephrotoxicity, ototoxicity and neurotoxicity following
IV infusion.227 Accumulation in malignant tissues was observed,
with platinum levels on average 10–50 times greater in tumours
than adjacent normal tissues, and up to 200 times greater in
colon cancers.227 Gastric tumours displayed the highest levels of
total platinum (up to 260 mg/g tissue) suggesting Lipoplatin as a
candidate for gastric tumours.227
Phase II trials have examined the effectiveness of Lipoplatin
against NSCLC. One such study did not recommend progression
to Phase III studies, with only a 5% PR rate and 16% stable
disease rate out of 19 pretreated patients.228 Improved activity
was shown when combining 120 mg m-2 Lipoplatin on days 1,
8 and 15 with gemcitabine 1000 mg m-2 on days 1 and 8 of
a three-week cycle (LipoGem). This regime showed a disease
control rate (DCR) of 71%.229 This was compared to a 32%
DCR in a cisplatin/gemcitabine (CisGem) control study.229 The
LipoGem regime continued to show slight superior activity over
CisGem in Phase III across a variety of histological NSCLC
subtypes, excluding squamous cell carcinomas.230 A safety proﬁle
more favourable than cisplatin was also observed, with particular
regard to nephrotoxicity, neurotoxicity and asthenia.230 Lipoplatin
has also been studied with gemcitabine for malignant pleural
mesothelioma, where a response was observed in one patient.231
Phase III trials in squamous cell carcinoma of the head and
neck (SCCHN) compared Lipoplatin 100 mg m-2/d (days 1, 8,
15) and 1000 mg m-2/d 5-FU (days 1–5) to a cisplatin/5-FU
regime.232,233 Lipoplatin/5-FU was associated with reduced renal
and haematological toxicity compared with cisplatin/5-FU232,233
and reduced occurrence of ototoxicity.232 Lipoplatin regimes also
displayed reduced nephrotoxicity,229,230 vomiting and/or nausea
and asthenia compared with cisplatin controls.219,220
Concurrent Lipoplatin, 5-FU and radiotherapy has been stud-
ied recently in Phase I/II trials for the treatment of locally
advanced gastric cancer.234 Twelve patients were treated with
Lipoplatin at a dose of 120 mg m-2 week-1, 5-FU at 400 mg
m-2 week-1 (day 1), and radiotherapy was given through 3.5-
Gy fractions on days 2, 3, and 4.234 Minimal nephrotoxicity and
neutropenia were reported.234 Response rates reached 80% tumour
disappearance in patients receiving ﬁve cycles, supporting further
studies of Lipoplatin in adjuvant postoperative or preoperative
radio-chemotherapy regimes for the treatment of gastric cancer.234
Conclusions
The design and synthesis of platinum anticancer drugs is very
much a mature ﬁeld. In the 40 years since the discovery of
cisplatin only six drugs have gained marketing approval whereas
14 were discontinued during clinical trials. All of these drugs
demonstrate severe side effects which greatly limit the dose which
can be administered, thereby reducing the effectiveness of the
drugs. This is because the basic chemical structure of all platinum
drugs is the same; amine carrier ligands with chlorido, sulfato
or dicarboxylato leaving groups. In addition, of those drugs that
are close to gaining approval (satraplatin and picoplatin) the leap
from Phase III to marketing is getting harder and longer because
of more stringent requirements to demonstrate not just improved
quality of life for the patient but also improved survival rates.
Whilst there will always be a need for new platinum drugs, no
new small molecule platinum drug has entered clinical trials since
1999 (BBR3464). Instead, the last decade has witnessed a shift
in focus towards the use of delivery vehicles, and three of these
types of “drugs” (Aroplatin, Lipoplatin and ProLindac) entered
clinical trials during this time. As can be seen in our perspective,
these generally demonstrate far fewer and less severe side effects
than the native drugs whilst also maintaining their cancer killing
ability.
The development of new and better delivery vehicles for
platinum drugs will rely almost entirely on inorganic and physical
chemists, rather than pharmacists or medical researchers as the
issues are almost entirely chemical. Clever design of delivery
vehicles for platinum drugs will require chemists to develop
systems that are able to: ensure the resultant drug-delivery vehicle
complexes are soluble in and biocompatible with physiological
media, control the overall size and shape of the drug-delivery
vehicle complexes, ensure the platinum drugs are released intact
from the delivery vehicle and without changing the drug active
component after aquation, control the rate and location of drug
release, and ﬁnally ensure they are stable against degradation in
storage and in vivo.
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